Reference : Rapport benefice/risque des endoprotheses coronaires pharmaco-actives. 1ere partie: a...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Pharmacy, pharmacology & toxicology
Rapport benefice/risque des endoprotheses coronaires pharmaco-actives. 1ere partie: analyse dans la population generale.
[en] Benefit-risk ratio of coronary drug-eluting stents. 1st part: evaluation in the global population
Nyssen, Astrid mailto [Université de Liège - ULiège > > > 3 doc médecine >]
Legrand, Victor mailto [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Revue Médicale de Liège
Yes (verified by ORBi)
[en] Angioplasty ; Coronary Artery Disease ; Paclitaxel ; Restenosis ; Sirolimus ; Stent ; Thrombosis
[en] Coronary drug-eluting stents (DES) are increasingly used in interventional cardiology. Stents coated with pharmacological substances such as sirolimus or paclitaxel, capable of reducing endothelial proliferation, have been proposed to replace bare-metal stents (BMS) in order to reduce the risk of restenosis. The survey of the literature confirms a major and significant reduction in the risk of restenosis with both sirolimus and paclitaxel DES as compared to BMS in the global population. This effect leads to a diminished requirement for new revascularisation procedures. However, such DES may increase the risk of very late stent thrombosis, presumably due to a defect of endothelialisation, which requires long-term effective antiplatelet therapy. The impact on major clinical coronary events shows no significant difference in mortality between DES and BMS. However, the incidence of myocardial infarct may be, slightly but significantly, reduced with sirolimus DES. In a next paper, the same analysis will be specifically performed in the diabetic population, which is well known to be at high risk of coronary heart disease, but is also expected to particularly benefit from DES.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
200809_05.pdfNo commentaryPublisher postprint367.26 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.